These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

577 related articles for article (PubMed ID: 23091029)

  • 21. Outcome of the p53-mediated DNA damage response in neuroblastoma is determined by morphological subtype and MYCN expression.
    Carr-Wilkinson J; Griffiths R; Elston R; Gamble LD; Goranov B; Redfern CP; Lunec J; Tweddle DA
    Cell Cycle; 2011 Nov; 10(21):3778-87. PubMed ID: 22052359
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MYCN controls an alternative RNA splicing program in high-risk metastatic neuroblastoma.
    Zhang S; Wei JS; Li SQ; Badgett TC; Song YK; Agarwal S; Coarfa C; Tolman C; Hurd L; Liao H; He J; Wen X; Liu Z; Thiele CJ; Westermann F; Asgharzadeh S; Seeger RC; Maris JM; Guidry Auvil JM; Smith MA; Kolaczyk ED; Shohet J; Khan J
    Cancer Lett; 2016 Feb; 371(2):214-24. PubMed ID: 26683771
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dickkopf-1 is down-regulated by MYCN and inhibits neuroblastoma cell proliferation.
    Koppen A; Ait-Aissa R; Hopman S; Koster J; Haneveld F; Versteeg R; Valentijn LJ
    Cancer Lett; 2007 Oct; 256(2):218-28. PubMed ID: 17643814
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biological effects of induced MYCN hyper-expression in MYCN-amplified neuroblastomas.
    Torres J; Regan PL; Edo R; Leonhardt P; Jeng EI; Rappaport EF; Ikegaki N; Tang XX
    Int J Oncol; 2010 Oct; 37(4):983-91. PubMed ID: 20811720
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MYCN-directed centrosome amplification requires MDM2-mediated suppression of p53 activity in neuroblastoma cells.
    Slack AD; Chen Z; Ludwig AD; Hicks J; Shohet JM
    Cancer Res; 2007 Mar; 67(6):2448-55. PubMed ID: 17363562
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vasoactive intestinal peptide decreases MYCN expression and synergizes with retinoic acid in a human MYCN-amplified neuroblastoma cell line.
    Chevrier L; Meunier AC; Cochaud S; Muller JM; Chadéneau C
    Int J Oncol; 2008 Nov; 33(5):1081-9. PubMed ID: 18949372
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TWIST1 is a direct transcriptional target of MYCN and MYC in neuroblastoma.
    Selmi A; de Saint-Jean M; Jallas AC; Garin E; Hogarty MD; Bénard J; Puisieux A; Marabelle A; Valsesia-Wittmann S
    Cancer Lett; 2015 Feb; 357(1):412-418. PubMed ID: 25475555
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Functional interplay between MYCN, NCYM, and OCT4 promotes aggressiveness of human neuroblastomas.
    Kaneko Y; Suenaga Y; Islam SM; Matsumoto D; Nakamura Y; Ohira M; Yokoi S; Nakagawara A
    Cancer Sci; 2015 Jul; 106(7):840-7. PubMed ID: 25880909
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multiple mechanisms disrupt the let-7 microRNA family in neuroblastoma.
    Powers JT; Tsanov KM; Pearson DS; Roels F; Spina CS; Ebright R; Seligson M; de Soysa Y; Cahan P; Theißen J; Tu HC; Han A; Kurek KC; LaPier GS; Osborne JK; Ross SJ; Cesana M; Collins JJ; Berthold F; Daley GQ
    Nature; 2016 Jul; 535(7611):246-51. PubMed ID: 27383785
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models.
    Wyce A; Ganji G; Smitheman KN; Chung CW; Korenchuk S; Bai Y; Barbash O; Le B; Craggs PD; McCabe MT; Kennedy-Wilson KM; Sanchez LV; Gosmini RL; Parr N; McHugh CF; Dhanak D; Prinjha RK; Auger KR; Tummino PJ
    PLoS One; 2013; 8(8):e72967. PubMed ID: 24009722
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Does MYCN amplification manifested as homogeneously staining regions at diagnosis predict a worse outcome in children with neuroblastoma? A Children's Oncology Group study.
    Moreau LA; McGrady P; London WB; Shimada H; Cohn SL; Maris JM; Diller L; Look AT; George RE
    Clin Cancer Res; 2006 Oct; 12(19):5693-7. PubMed ID: 17020972
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MYCN is recruited to the RASSF1A promoter but is not critical for DNA hypermethylation in neuroblastoma.
    Charlet J; Szemes M; Malik KT; Brown KW
    Mol Carcinog; 2014 May; 53(5):413-20. PubMed ID: 23280764
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined IFN-gamma and retinoic acid treatment targets the N-Myc/Max/Mad1 network resulting in repression of N-Myc target genes in MYCN-amplified neuroblastoma cells.
    Cetinkaya C; Hultquist A; Su Y; Wu S; Bahram F; Påhlman S; Guzhova I; Larsson LG
    Mol Cancer Ther; 2007 Oct; 6(10):2634-41. PubMed ID: 17938259
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clustering of gene hypermethylation associated with clinical risk groups in neuroblastoma.
    Alaminos M; Davalos V; Cheung NK; Gerald WL; Esteller M
    J Natl Cancer Inst; 2004 Aug; 96(16):1208-19. PubMed ID: 15316056
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neuroblastomas with discordant genotype-phenotype relationships: report of four cases with MYCN amplification and favorable histology.
    Nakagawa A; Matsuoka K; Okita H; Iwafuchi H; Hori H; Kumagai M
    Pediatr Dev Pathol; 2011; 14(2):87-92. PubMed ID: 21288077
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is MYCN Overexpression Associated With Poor Outcome in
    Andrews A; Terry J
    Pediatr Dev Pathol; 2024; 27(3):282-283. PubMed ID: 38360554
    [No Abstract]   [Full Text] [Related]  

  • 37. The MYCN oncogene and differentiation in neuroblastoma.
    Westermark UK; Wilhelm M; Frenzel A; Henriksson MA
    Semin Cancer Biol; 2011 Oct; 21(4):256-66. PubMed ID: 21849159
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human neuroblastoma cells with MYCN amplification are selectively resistant to oxidative stress by transcriptionally up-regulating glutamate cysteine ligase.
    Veas-Perez de Tudela M; Delgado-Esteban M; Cuende J; Bolaños JP; Almeida A
    J Neurochem; 2010 May; 113(4):819-25. PubMed ID: 20180881
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neuroblastoma and MYCN.
    Huang M; Weiss WA
    Cold Spring Harb Perspect Med; 2013 Oct; 3(10):a014415. PubMed ID: 24086065
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Coamplification of DDX1 correlates with an improved survival probability in children with MYCN-amplified human neuroblastoma.
    Weber A; Imisch P; Bergmann E; Christiansen H
    J Clin Oncol; 2004 Jul; 22(13):2681-90. PubMed ID: 15226335
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.